Atria Investments’s Biogen BIIB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $447K | Sell |
2,437
-766
| -24% | -$141K | 0.01% | 1507 |
|
|
2025
Q4 | $564K | Buy |
3,203
+1,414
| +79% | +$231K | 0.01% | 1366 |
|
|
2025
Q3 | $251K | Sell |
1,789
-151
| -8% | -$20.4K | ﹤0.01% | 1823 |
|
|
2025
Q2 | $244K | Buy |
1,940
+243
| +14% | +$30.3K | ﹤0.01% | 1815 |
|
|
2025
Q1 | $232K | Sell |
1,697
-126
| -7% | -$18K | ﹤0.01% | 1751 |
|
|
2024
Q4 | $279K | Sell |
1,823
-1,715
| -48% | -$289K | ﹤0.01% | 1626 |
|
|
2024
Q3 | $686K | Sell |
3,538
-827
| -19% | -$173K | 0.01% | 1171 |
|
|
2024
Q2 | $1.01M | Buy |
+4,365
| New | +$949K | 0.01% | 919 |
|
|
2024
Q1 | – | Sell |
-4,374
| Closed | -$1.13M | – | 967 |
|
|
2023
Q4 | $1.13M | Buy |
+4,374
| New | +$1.07M | 0.02% | 842 |
|
|
2021
Q4 | – | Sell |
-7,793
| Closed | -$2.21M | – | 843 |
|
|
2021
Q3 | $2.21M | Buy |
7,793
+3,830
| +97% | +$1.26M | 0.04% | 488 |
|
|
2021
Q2 | $1.37M | Sell |
3,963
-2,300
| -37% | -$697K | 0.03% | 649 |
|
|
2021
Q1 | $1.75M | Sell |
6,263
-2,267
| -27% | -$611K | 0.04% | 499 |
|
|
2020
Q4 | $2.09M | Buy |
8,530
+2,629
| +45% | +$678K | 0.05% | 405 |
|
|
2020
Q3 | $1.67M | Buy |
5,901
+122
| +2% | +$34K | 0.05% | 391 |
|
|
2020
Q2 | $1.55M | Buy |
5,779
+167
| +3% | +$50.2K | 0.05% | 373 |
|
|
2020
Q1 | $1.77M | Sell |
5,612
-1,738
| -24% | -$527K | 0.14% | 150 |
|
|
2019
Q4 | $2.18M | Buy |
7,350
+1,894
| +35% | +$526K | 0.06% | 282 |
|
|
2019
Q3 | $1.27M | Sell |
5,456
-462
| -8% | -$108K | 0.05% | 349 |
|
|
2019
Q2 | $1.35M | Sell |
5,918
-1,984
| -25% | -$458K | 0.05% | 314 |
|
|
2019
Q1 | $1.87M | Buy |
7,902
+803
| +11% | +$253K | 0.08% | 222 |
|
|
2018
Q4 | $2.14M | Buy |
7,099
+1,449
| +26% | +$462K | 0.09% | 172 |
|
|
2018
Q3 | $2M | Buy |
5,650
+1,910
| +51% | +$658K | 0.08% | 228 |
|
|
2018
Q2 | $1.08M | Sell |
3,740
-1,874
| -33% | -$527K | 0.05% | 361 |
|
|
2018
Q1 | $1.54M | Buy |
5,614
+858
| +18% | +$266K | 0.07% | 253 |
|
|
2017
Q4 | $1.51M | Buy |
4,756
+950
| +25% | +$305K | 0.08% | 256 |
|
|
2017
Q3 | $1.19M | Buy |
3,806
+900
| +31% | +$267K | 0.06% | 274 |
|
|
2017
Q2 | $789K | Buy |
2,906
+957
| +49% | +$253K | 0.05% | 338 |
|
|
2017
Q1 | $533K | Buy |
1,949
+422
| +28% | +$119K | 0.03% | 385 |
|
|
2016
Q4 | $433K | Buy |
1,527
+254
| +20% | +$75.3K | 0.03% | 374 |
|
|
2016
Q3 | $398K | Buy |
1,273
+257
| +25% | +$76.1K | 0.04% | 350 |
|
|
2016
Q2 | $253K | Sell |
1,016
-258
| -20% | -$68K | 0.03% | 395 |
|
|
2016
Q1 | $332K | Buy |
1,274
+374
| +42% | +$98.8K | 0.04% | 343 |
|
|
2015
Q4 | $253K | Buy |
900
+193
| +27% | +$55.5K | 0.03% | 343 |
|
|
2015
Q3 | $206K | Sell |
707
-181
| -20% | -$59.8K | 0.03% | 325 |
|
|
2015
Q2 | $359K | Buy |
888
+307
| +53% | +$123K | 0.04% | 291 |
|
|
2015
Q1 | $245K | Buy |
+581
| New | +$229K | 0.03% | 359 |
|
|
2014
Q4 | – | Sell |
-608
| Closed | -$201K | – | 416 |
|
|
2014
Q3 | $201K | Buy |
+608
| New | +$200K | 0.02% | 442 |
|
Other funds holding BIIB
VCM
VPM
Atria Investments's BIIB Position: Q1 2026 in Review
Atria Investments reduced its Biogen (BIIB) stake by 24% in Q1 2026, selling an estimated $141K and leaving 2,437 shares worth $447K. The position accounts for 0.01% of the portfolio, ranked #1507.
Atria Investments first reported a position in BIIB in Q3 2014 and has held it in 37 quarters since. The position peaked at $2.21M in Q3 2021. 1,002 funds tracked by Wall St. Rank hold BIIB as of Q1 2026.
- Atria Investments held 2,437 shares of Biogen worth $447K as of Q1 2026.
- Atria Investments sold 766 Biogen shares in Q1 2026, an estimated $141K.
- Biogen made up 0.01% of Atria Investments's portfolio in Q1 2026, its #1507 holding.
- Atria Investments first reported a position in Biogen in Q3 2014 and has held it in 37 quarters since.
- Atria Investments's Biogen position peaked at $2.21M in Q3 2021.
- 1,002 funds tracked by Wall St. Rank held Biogen as of Q1 2026.
Based on Atria Investments's 13F filing for Q1 2026, filed 5 May 2026.